Core Insights - The medical services sector experienced a slight increase of 0.29% on September 16, with Chengda Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Medical Services Sector Performance - Chengda Pharmaceutical (301201) closed at 33.32, with a significant increase of 15.25% and a trading volume of 157,100 shares, amounting to a transaction value of 508 million yuan [1] - Haocen Medical (002622) saw a rise of 10.10%, closing at 4.25 with a trading volume of 993,200 shares, totaling 409 million yuan [1] - Aoyang Health (002172) increased by 10.00%, closing at 4.73 with a trading volume of 87,500 shares, amounting to 41.39 million yuan [1] - Bid Pharma (688073) rose by 6.48%, closing at 74.73 with a trading volume of 26,000 shares, totaling 192 million yuan [1] - Yikang Biological (688046) increased by 5.56%, closing at 19.75 with a trading volume of 79,600 shares, amounting to 158 million yuan [1] - Other notable performers include Haoyuan Pharmaceutical (688131) with a 4.44% increase, closing at 78.28, and Xinlicheng (002219) with a 3.46% increase, closing at 2.39 [1] Fund Flow Analysis - The medical services sector saw a net outflow of 228 million yuan from institutional investors, while retail investors contributed a net inflow of 59.64 million yuan [3] - Speculative funds recorded a net inflow of 168 million yuan into the sector [3]

Core Points - The company is changing its official website and investor email domain to enhance its brand image [1] - The new website and email will be effective from September 15, 2025, with a transition period until March 15, 2026 [1] - During the transition, the old website will automatically redirect to the new one, and emails sent to the old investor email will be forwarded to the new one [1] - The company's investor contact number, fax, and address will remain unchanged [1]

证券代码：688710 证券简称：益诺思 上海益诺思生物技术股份有限公司 2025 年第三次临时股东大会会议资料 2025 年第三次临时股东大会会议资料目录 | 2025年第三次临时股东大会须知 | | 3 | | --- | --- | --- | | 2025年第三次临时股东大会会议议程 | | 5 | | 议案一：关于续聘会计师事务所的议案 | | 6 | | 议案二：关于购买董监高责任险的议案 | | 7 | 上海益诺思生物技术股份有限公司 2025 年第三次临时股东大会 会议资料 二〇二五年九月 七、股东发言由大会主持人组织，股东发言时应先报告所持股票数量和持 股人名称。股东在股东大会上的发言，应围绕本次大会所审议的议案，简明扼 要，时间原则上不超过 5 分钟，经主持人同意后方可延长发言时间。主持人可 安排公司董事、监事和其他高级管理人员等回答股东问题，与本次股东大会议 题无关或涉及国家秘密、公司商业秘密或可能损害公司、股东利益的问题，大 上海益诺思生物技术股份有限公司 2025 年第三次临时股东大会会议资料 2025年第三次临时股东大会须知 根据中国证券监督管理委员会《上市公司股东大会规则》和《公 ...

证券代码：688710 证券简称：益诺思 公告编号：2025-033 上海益诺思生物技术股份有限公司 关于变更公司网址及投资者邮箱的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海益诺思生物技术股份有限公司董事会 2025年9月13日 上海益诺思生物技术股份有限公司（以下简称"公司"）为进一步提升公司 品牌形象，经公司研究决定，对公司官方网址及企业邮箱域名进行变更。现将具 体相关情况公告如下： | 变更内容 | 变更前 | 变更后 | | --- | --- | --- | | 公司官方网址 | www.innostar.cn | www.innostarbio.com | | 投资者邮箱 | bo@innostar.cn | bo@innostarbio.com | 变更后的公司官方网址及投资者邮箱将于2025年9月15日起正式启用，为保 障访问与沟通顺畅，过渡期为2025年9月15日至2026年3月15日，过渡期内访问原 官方网址将自动跳转至新网址，原投资者邮箱信件将同步至新投资者邮箱，确保 信息传递不受影响 ...

Company Overview - Yinos Bio is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 12, 2010. The company went public on September 3, 2024. Its main business involves providing non-clinical research services in the biopharmaceutical sector, primarily as a Contract Research Organization (CRO) [1] - The revenue composition of Yinos Bio is as follows: non-clinical services account for 96.31%, clinical services for 3.42%, and other services for 0.27% [1] Financial Performance - As of June 30, 2025, Yinos Bio reported a revenue of 375 million yuan, a year-on-year decrease of 38.04%. The net profit attributable to shareholders was -15.19 million yuan, representing a year-on-year decrease of 115.88% [2] - Since its A-share listing, Yinos Bio has distributed a total of 45.11 million yuan in dividends [3] Stock Performance - On September 12, Yinos Bio's stock price increased by 2.02%, reaching 39.98 yuan per share, with a trading volume of 46.57 million yuan and a turnover rate of 1.31%. The total market capitalization is 5.636 billion yuan [1] - Year-to-date, Yinos Bio's stock price has risen by 13.61%. However, it has seen a decline of 0.10% over the last five trading days and an 8.89% decrease over the last 20 days, while it has increased by 27.94% over the last 60 days [1] Shareholder Structure - As of June 30, 2025, the number of shareholders for Yinos Bio was 5,386, a decrease of 0.90% from the previous period. The average number of circulating shares per person increased by 0.91% to 5,235 shares [2] - Among the top ten circulating shareholders, ICBC Medical Health Stock (000831) is the seventh largest with 439,400 shares, an increase of 72,300 shares from the previous period. New entrants include ICBC Strategic Transformation Stock A (000991) and Harvest Medical Health Stock A (005303) [3]

Core Viewpoint - The company reported a revenue of 380 million yuan in 25H1, a year-on-year decrease of 38.0%, and a net profit attributable to shareholders of -15.19 million yuan, down 115.9% year-on-year, indicating a significant decline in performance due to a slowdown in domestic investment and financing, as well as increased market competition leading to lower sales order prices. The company is expected to benefit from improvements in domestic financing and increased investment in innovative drug development, potentially entering a new growth cycle with the ramp-up of capacity in Nantong Phase II [1] Group 1: New Orders and International Expansion - The company signed new orders worth 530 million yuan in 25H1, representing a year-on-year increase of 7.4%. The number of new projects in core businesses IND and NDA grew by 6.9% year-on-year. Notably, the number of new projects for small nucleic acid drugs and radioactive drugs showed significant growth, becoming new growth points. The company accelerated its overseas business development by expanding its international marketing network and participating in six major conferences, which helped to rapidly expand its global customer base [2] Group 2: Capacity Construction and R&D Innovation - The company is steadily advancing its capacity construction, with the Nantong Phase II facility of 24,000 square meters obtaining the experimental animal use license and entering the GLP simulation operation phase, expected to ramp up production in early 26. The expansion of the 1,800 square meter isotope facility and the construction of a new comprehensive laboratory in Huangshan are also underway. Additionally, the company increased its R&D investment, with R&D expenses accounting for 5.9% of revenue in 25H1, up 2.3 percentage points year-on-year, and has made progress in various innovative projects [3] Group 3: Profit Forecast and Investment Recommendations - Based on the mid-year report for 25, the company has adjusted its revenue and gross margin forecasts downward while raising expense forecasts. The earnings per share estimates for 2025-2027 have been revised to 0.14/0.94/1.41 yuan, compared to previous estimates of 0.99/1.16/1.42 yuan. The target price is set at 43.24 yuan based on a 46 times PE ratio for comparable companies in 26, maintaining a "buy" rating [4]

Core Viewpoint - Yinosh experienced a slight increase in stock price on September 11, with a trading volume of 63.42 million yuan, indicating ongoing market activity despite financial challenges [1] Group 1: Financial Performance - For the first half of 2025, Yinosh reported a revenue of 375 million yuan, representing a year-on-year decrease of 38.04% [2] - The company recorded a net profit attributable to shareholders of -15.19 million yuan, a significant decline of 115.88% compared to the previous period [2] Group 2: Shareholder and Market Activity - As of June 30, 2025, Yinosh had 5,386 shareholders, a decrease of 0.90% from the previous period, while the average number of circulating shares per shareholder increased by 0.91% to 5,235 shares [2] - On September 11, Yinosh's financing buy-in amounted to 4.74 million yuan, with a net financing buy of -1.48 million yuan, indicating more repayments than new purchases [1] - The total balance of margin trading for Yinosh reached 87.06 million yuan, accounting for 2.45% of its market capitalization [1] Group 3: Shareholder Composition - As of June 30, 2025, the top ten circulating shareholders included ICBC Medical Health Stock, which increased its holdings by 72,300 shares to 439,400 shares [3] - New entrants among the top ten shareholders included ICBC Strategic Transformation Stock and Harvest Medical Health Stock, holding 354,100 shares and 344,300 shares respectively [3] - Notably, several funds such as Agricultural Bank Medical Health Stock and others exited the top ten circulating shareholders list [3]

Group 1 - On September 10, Yinos achieved a stock price increase of 3.57% with a trading volume of 79.4568 million yuan, and the net financing purchase amounted to 3.0738 million yuan [1] - As of September 10, the total balance of margin trading for Yinos was 88.5422 million yuan, which represents 2.51% of its circulating market value [1] - Yinos primarily operates in the field of biopharmaceutical non-clinical research services, with 96.31% of its revenue coming from non-clinical services [1] Group 2 - As of June 30, Yinos had 5,386 shareholders, a decrease of 0.90% from the previous period, while the average circulating shares per person increased by 0.91% to 5,235 shares [2] - For the first half of 2025, Yinos reported a revenue of 375 million yuan, a year-on-year decrease of 38.04%, and a net profit attributable to shareholders of -15.1895 million yuan, a decline of 115.88% [2] - After its A-share listing, Yinos has distributed a total of 45.1135 million yuan in dividends [2]

Core Viewpoint - The article discusses the upcoming 2025 Shanghai Leading Industries and the 14th Pharmaceutical CEO Forum, highlighting the focus on innovation and global expansion of Chinese pharmaceutical companies [1]. Summary by Sections Event Overview - The event will take place on September 4-5, 2025, at the Mandarin Oriental Hotel in Pudong, Shanghai, featuring nearly a hundred executives from listed companies, including chairpersons, CEOs, and industry leaders [4]. Morning Sessions - The morning session on September 4 will include a keynote speech and several roundtable discussions focusing on topics such as the global expansion of Chinese pharmaceutical companies and the search for the next billion-dollar drug [4][5]. - Notable discussions will include: - "From Local Innovation to Global Leadership: The Era of Chinese Pharmaceutical Companies Going Abroad" [4]. - "The Birth of Big Drugs is the Future of Pharmaceuticals: Finding the Next Billion-Dollar Bomb" [4]. Afternoon Sessions - The afternoon will feature discussions on future disease areas and technologies worth exploring for pharmaceutical assets going abroad, as well as the new cycle of Chinese innovative drugs under global competition [5][6]. - Additional topics will cover advancements in drug development platforms and the emerging field of brain-machine interfaces [6]. TMT Forum - The TMT (Technology, Media, and Telecommunications) forum will also take place, discussing AI's impact on various industries, including gaming and healthcare [7][8]. - Key topics will include AI innovations in mobile internet ecosystems and the future of AI in healthcare [7]. Pharmaceutical Sub-Forum - The pharmaceutical sub-forum will address topics such as ADC technology exploration, probiotic delivery systems, and the future development paths of dual antibodies and XDC [8]. - Discussions will also focus on the integration of medical insurance and the innovative practices in building a multi-level medical security system in China [8].

Group 1 - The core viewpoint of the news is that Yinosh has experienced a decline in stock price and financial performance, with significant changes in financing and shareholder structure [1][2][3] - As of September 2, Yinosh's stock price fell by 2.24%, with a trading volume of 58.6354 million yuan. The net financing buy was -3.902 million yuan, indicating a higher repayment than new purchases [1] - Yinosh's financing balance reached 86.1492 million yuan, accounting for 7.59% of its market capitalization, with no short selling activity reported on the same day [1] Group 2 - For the first half of 2025, Yinosh reported a revenue of 375 million yuan, a year-on-year decrease of 38.04%, and a net profit attributable to shareholders of -15.1895 million yuan, a decline of 115.88% [2] - As of June 30, 2025, the number of Yinosh shareholders was 5,386, a decrease of 0.90%, while the average circulating shares per person increased by 0.91% to 5,235 shares [2] - Yinosh has distributed a total of 45.1135 million yuan in dividends since its A-share listing, with changes in institutional holdings noted among its top shareholders [3]